Lifetime probabilities of developing and dying from cancer in China: comparison with Japan and the United States in 2022
Qian Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenqiang Wei(Chinese Academy of Medical Sciences & Peking Union Medical College), Rongshou Zheng(Chinese Academy of Medical Sciences & Peking Union Medical College), Bingfeng Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Ru Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Shaoming Wang(Shihezi University), Kexin Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Yifei Yao(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 8
Related Papers
Cancer incidence and mortality in China, 2022
|Journal of the National Cancer Center|2024|2k
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k
Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020
|Cancer Communications|2021|1.1k
Cancer registration in China and its role in cancer prevention and control
|The Lancet Oncology|2020|501
Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN
|The Lancet. Gastroenterology & hepatology|2024|248